New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 25, 2013
04:55 EDTAET, AET, AET, SGYP, SGYP, SGYP, SYK, SYK, SYK, EW, EW, EW, CCXI, CCXI, CCXI, INFI, INFI, INFI, QSII, QSII, QSII, SIAL, SIAL, SIALCitigroup to host a conference
Global Healthcare Conference is being held in New York on February 25-27.
News For EW;CCXI;INFI;QSII;SIAL;AET;SGYP;SYK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
October 21, 2014
08:39 EDTCCXIChemoCentryx reports CCX507 well tolerated, effective in Phase I study
Subscribe for More Information
06:06 EDTSGYPSynergy Pharm' presents positive data from phase 2b study of plecanatide
Synergy Pharmaceuticals announced the presentation of results from a phase 2b dose-ranging study assessing plecanatide’s safety and efficacy in 424 adult patients with irritable bowel syndrome with constipation. Data presented at ACG demonstrate that plecanatide, once-daily oral tablet, significantly improved complete spontaneous bowel movement frequency, bowel habits, treatment satisfaction and significantly reduced abdominal pain in patients with IBS-C throughout the 12 week treatment period. Notably, patients taking 3.0 and 9.0 mg plecanatide showed statistically significant improvement in the Overall Responder rate, a secondary analysis in this study and the endpoint required for FDA approval in IBS-C.
05:19 EDTQSIIQuality Systems dental division announces strategic partnership with Patterson
Subscribe for More Information
October 20, 2014
08:37 EDTCCXIChemoCentryx releases Phase III SHIELD 4 clinical results
ChemoCentryx reported data from the Phase III SHIELD 4 clinical trial in Crohn's disease with vercirnon, an inhibitor of the chemokine receptor known as CCR9. Data showed that patients experienced improved response and remission rates when taking a higher dose of vercirnon. There was no evidence of higher gastrointestinal, hepatic, or cardiovascular adverse events with the twice daily group compared to the once daily group. Thomas J. Schall, Ph.D., president and CEO stated, "These SHIELD 4 data are consistent with our earlier positive PROTECT-1 study data. As with PROTECT-1, the data indicate that vercirnon is safe and well tolerated in patients with Crohn's disease, and there is a dose-dependent improvement in symptoms in the observed patient population in SHIELD 4. The Phase III drug CCX282/vercirnon, in addition to our second-generation, Phase II-ready CCR9 inhibitor, CCX507, provide a strong complement of drugs in our CCR9 program for which we intend to find a strategic partner."
07:12 EDTSYKCongress of Neurological Surgeons to hold annual meeting
Subscribe for More Information
07:04 EDTINFIInfinity Pharmaceuticals coverage resumed with a Hold at Stifel
October 17, 2014
07:45 EDTSYKStryker price target lowered to $84 from $88 at Canaccord
Subscribe for More Information
05:20 EDTQSII NextGen Healthcare, InterSystems demonstrate cross-vendor interoperability
Subscribe for More Information
October 16, 2014
16:04 EDTSYKStryker sees FY14 adjusted EPS at low end of $4.75-$4.80 guidance
Subscribe for More Information
16:02 EDTSYKStryker reports Q3 adjusted EPS $1.15, consensus $1.14
Reports Q3 revenue $2.39B, consensus $2.32B.
15:26 EDTSYKNotable companies reporting after market close
Subscribe for More Information
07:41 EDTINFIInfinity reports duvelisib Phase 2a primary endpoint not met
Infinity Pharmaceuticals announced encouraging topline data from its Phase 2a exploratory study of duvelisib, or IPI-145. Data from this randomized, double-blind, placebo-controlled, cross-over study demonstrated that duvelisib was well tolerated and met several secondary and exploratory endpoints in an allergen challenge study. Clinical improvement was observed in the late-phase asthmatic response FEV1 among patients who received duvelisib administered at the highest dose tested, 25 mg twice daily for five days, however the primary endpoint of the study was not met as it did not reach statistical significance. Multiple secondary clinical endpoints measuring improvements in lung function following duvelisib administration were achieved with statistical significance and were associated with changes in key cytokines and chemokines involved in the asthmatic response. Taken together, these data demonstrate early proof-of-activity in this allergen challenge study. Infinity expects to present the final data in a peer-reviewed setting after all analyses are complete. In addition, the company anticipates determining its next steps for development of PI3K-delta,gamma inhibitors in inflammation after evaluating the results from the ASPIRA study in rheumatoid arthritis, which are expected by the end of 2014.
October 15, 2014
13:52 EDTAETAetna will not renew contract for Delaware Medicaid program
Subscribe for More Information
October 14, 2014
12:33 EDTSYKZimmer, Stryker have postive read-through from J&J, says Wells Fargo
Subscribe for More Information
11:11 EDTSYKJohnson & Johnson Ortho strength positive for Zimmer, says Piper Jaffray
Piper Jaffray said Johnson & Johnson's (JNJ) sequential Q3 strength in orthopedics, which included acceleration in both hips and knees, was surprising and a positive for Zimmer (ZMH). However, Piper expect sentiments on ortho names to remain muted until further into reporting season, noting that Stryker (SYK) is scheduled to report Thursday after the close. The firm has Neutral rating on Johnson & Johnson and Stryker and an Overweight rating on Zimmer.
October 13, 2014
13:05 EDTINFIInfinity Pharmaceuticals management to meet with ISI Group
Subscribe for More Information
07:37 EDTEWAmerican Society of Anesthesiologists to hold annual meeting
Subscribe for More Information
October 10, 2014
07:16 EDTSYKAmerican Society of Plastic Surgeons to hold annual meeting
Annual Meeting of ASPS is being held in Chicago on October 10-14.
October 9, 2014
08:03 EDTAETWellPoint named top Managed Care pick at Jefferies
Subscribe for More Information
06:18 EDTSYKBiomet reports Q1 sales up 6% to $775M
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use